Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Finance Committee Spars Over EHR Meaningful Use Timing

This article was originally published in The Gray Sheet

Executive Summary

A July 24 hearing provides jabs from senators and witnesses over pace of meaningful-use stage-two timing. The second stage of meaningful use requirements take force in October 2013 for hospitals, and January 2014 for all eligible professionals.

You may also be interested in...



Digital Health Briefs: Digital Health Funding Hits New High; FTC Mobile Apps Focus

Rock Health’s Q3 update shows that funding for digital health so far in 2013 has already outpaced 2012 full-year levels. FTC emphasizes interest in mobile app claims. Some Senators want HHS to delay stage 2 of the electronic medical records meaningful use requirements. More digital health news.

Digital Health In Brief

Philips Respironics launches mobile app for sleep apnea patients. GOP senators criticize Obama administration’s electronic health records program. More digital health news.

Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans

Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel